FUTURE PLANS AND VISION
Over forty years of existence of Medical Oncology, our department has delivered scientific advances and improved outcomes for patients, significantly increasing cancer survival and quality of life. Today's management ethos is multi modality interaction and patient care.
Multi-disciplinary treatment has been an integral part of the Cancer Institute and is an essential component of any state of the art Cancer centers.
However, the forces that fueled this progress are not the same as those that will shape the future we are on the verge of a new age of cancer care, in which emerging scientific, technical and economic trends are likely to alter our work more significantly in the next 10 years than in the prior 40.
Our goal is to be a world-class centre of clinical and academic achievement, where staff work together to ensure patients receive the highest standards of care and the best people want to come to learn, work and research.
Staying true to our values during a period of rapid reform will be critical to our success.
1. The Patient as "KING"
We must work to attract patients rather than adopting a paternalistic approach and choice will be based on more subtle and challenging criteria than we currently recognize. Rather than our reputation alone being the driving factor, infection rates, cleanliness, waiting times, privacy and dignity and communication will become equally important in the future. We will constantly improve patient care and foster innovation in providing the same.
2. KEEPING NEW TREATMENTS AFFORDABLE
3. ROUTINE QUALITY MEASUREMENT AND IMPROVEMENT
Objective Quality assessment in department for
4. SMARTER CARE, BETTER CARE
5. DM MEDICAL ONCOLOGY TRAINING PROGRAMS
6. RESEARCH AND INNOVATION
We have an excellent reputation for translational clinical research which turns discoveries in basic science into tangible improvements in patient care. This offers a significant opportunity for expansion and our ability to attract International Collaboration in Clinical Research.
We will work to develop our excellence in clinical research and collaborate with international academic institutions around scientific research.
7. TARGETTED THERAPY TODAY AND FUTURE PROSPECTS
Today, Available drugs target single mutations within the cancer genome, often resulting in only temporary delays in progression and limited impact on survival. By 2020 for common cancers, multiple targets and their interactions will be understood. Treatment combinations will be tailored to the individual patient's molecular pro?le.